Unlocking non-hormonal male contraception with HDAC inhibitors

The FDA has granted accelerated approval to tarlatamab (Imdelltra) as a third-line option for patients with extensive-stage small cell lung cancer (SCLC) with disease progression

People with a history of uveitis were more likely to experience recurrences of the potentially dangerous eye inflammation after vaccination against COVID-19, a retrospective population-based